Emergent BioSolutions | EBS - Selling And Administration Expenses


Emergent BioSolutions reported $182.8M in Selling and Administration Expenses for its fiscal quarter ending in June of 2023.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 160.79M 14.06M Mar/2026
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
ALKERMES USD 264.59M 77.4M Mar/2026
Alnylam Pharmaceuticals USD 282.51M 2.55M Mar/2026
Amarin USD 18.97M 1.03M Dec/2025
ANI Pharmaceuticals USD 73.66M 9.14M Mar/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Coherus Biosciences USD 15M 6.26M Dec/2025
Emergent BioSolutions USD 182.8M 82.3M Jun/2023
Exelixis USD 139.6M 16.58M Mar/2026
Glaxosmithkline GBP 2.12B 1.44B Mar/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Ionis Pharmaceuticals USD 151M 21M Mar/2026
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
Lexicon Pharmaceuticals USD 3.98M 195K Dec/2025
Merck USD 2.67B 180M Mar/2026
Moderna USD 173M 135M Mar/2026
Myriad Genetics USD 122.3M 6.7M Dec/2025
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Neurocrine Biosciences USD 318.5M 16.7M Mar/2026
Pacira USD 83.88M 7.99M Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Sanofi EUR 2.33B 419M Mar/2026
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
United Therapeutics USD 156.6M 34M Mar/2026
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024